EMEA-002350-PIP01-18-M01

Table of contents

Key facts

Active substance
Deucravacitinib
Therapeutic area
Dermatology
Decision number
P/0065/2021
PIP number
EMEA-002350-PIP01-18-M01
Pharmaceutical form(s)
  • Film-coated tablet
  • Age-appropriate oral solid dosage form
Condition(s) / indication(s)
Treatment of psoriasis
Route(s) of administration
Oral use
Contact for public enquiries
Bristol-Myers Squibb International Corporation

E-mail: medical.information@bms.com
Tel. +44 1423 533 610

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating
Average
1 rating